Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Defensins and Other Antimicrobial Peptides and Proteins

Robert I. Lehrer
Department of Medicine and Molecular Biology Institute, UCLA School of Medicine, Los Angeles, California

Charles L. Bevins
Departments of Immunology, Gastroenterology, and Colorectal Surgery, The Cleveland Clinic Foundation Research Institute, Cleveland, Ohio

Tomas Ganz
Departments of Medicine and Pathology, UCLA School of Medicine, Los Angeles, California

INTRODUCTION

Endogenous antimicrobial peptides are widely distributed among vertebrates. Most are amphiphilic, polycationic molecules with an α-helical, cystine-stabilized β-sheet, or proline-rich structure. They represent elements of a robust, ancestral animal immune system that predates the advent of lymphocytes and immunoglobulins. Secreted and cell-associated antimicrobial peptides enable their hosts to resist incursions by potential pathogens. From a pathogen’s perspective, these peptides present a series of barriers to evade or overcome. In humans (and other mammals), defensins and cathelicidins are the principal antimicrobial peptides of neutrophils and epithelial cells. Many mucosal surfaces are bathed by antimicrobial proteins, including lysozyme, lactoferrin, secretory leukoprotease inhibitor (SLPI), and secretory phospholipase A2.

Defensins

All defensins have a largely β-sheet structure and contain three intramolecular cystine disulfide bonds. The smallest, θ-defensins, are circular peptides that contain 18 residues, α-defensins have between 29 and 35 residues, and β-defensins have up to 45 (Fig. 6.1). To date, more than 100 α-defensin, β-defensin, and θ-defensin molecules have been reported, and humans express six different α-defensins and at least four β-defensins. Additional human defensin/defensinlike genes exist in five different chromosomal loci, but their expression and properties remain to be characterized. α-Defensins occur in the neutrophils of humans, rats, rabbits, guinea pigs, and hamsters, but not in those of mice, horses, pigs, and sheep. Although the small intestinal Paneth cells of mice express at least 6 (Ouellette et al. 2000; Selsted et al. 1992) and possibly as many as 20 α-defensins (Ouellette and Selsted 1996), only two very dissimilar defensin species are found in human Paneth cells (Mallow et al. 1996). Two atypical α-defensins exist in rabbit kidney, but their functions remain uncertain (Bateman et al. 1996; Wu et al. 1998). Thus far, with the exception of rabbit alveolar macrophages, mononuclear phagocytes are not known to produce appreciable amounts of α-defensins.

Although many human epithelial cells constitutively express human β-defensins (HBD-1), this peptide is particularly abundant in the distal renal tubules and in other parts of the genitourinary tract. HBD-2, originally recovered from psoriatic skin (Harder et al. 1997), is induced in various epithelia by inflammatory signals. In the epidermis, it is present in very low amounts unless induced by interleukin-1 (IL-1) (Liu et al. 2003). The HBD-3 gene was found by genomic searching (Jia et al. 2001) and the corresponding peptide was isolated from psoriatic skin (Harder et al. 2001). HBD-4 is highly expressed in the testis (epididymis) and less abundantly in the gastric antrum (Garcia et al. 2001b). Since about 50 different β-defensin genes have been identified in the mouse (Scheetz et al. 2002), sorting out their functions and relationships to human biology is unlikely to be a simple task.
**GENERAL PROPERTIES OF DEFENSINS**

**Structure of mature defensins**

Figure 6.1 shows the primary amino acid sequences of eleven defensins. The six α-defensins are of human origin: HNP 1–4 from leukocytes, and HD-5 and 6 from intestinal cells. The five β-defensins include human hBDs 1–3, bovine "tracheal antimicrobial peptide" (TAP), and gallinacin-2 from chicken leukocytes. The β-defensins are complexly folded, macrocyclic molecules.

By x-ray crystallography, human defensin HNP-3 is an elongated ellipsoid, 26 × 15 × 15 Å, dominated by a three-stranded, cystine-stabilized antiparallel β-sheet (Hill et al. 1991). The highly conserved Arg and Glu residues form a salt bridge spanning the only non-β-sheet portion of the molecule and the invariant glycine occupies the third position of a Type I turn. HNP-3 crystallizes as a dimer that figures a six-stranded β-sheet stabilized by hydrophobic interactions and hydrogen bonds. That the invariant glycine is located at the dimer interface suggests that dimer formation may be an essential element of defensin-mediated activity. A dimer of the human α-defensin HNP-3 is illustrated in Figure 6.2.

Crystallographic analyses of HBD-1 (Hoover et al. 2001) and HBD-2 (Hoover et al. 2000) found very similar structures for the monomers, including the presence of a short, N-terminal, α-helical segment not present in α-defensins. It is noteworthy that a similarly positioned helical region exists in the defensinlike antimicrobial peptides of insects and plants (e.g., wheat purothionine). The solution structures reported for HBDs 1, 2, and 3 show them to have similar tertiary structures, with a short helical segment preceding a three-stranded antiparallel beta-sheet (Schibli et al. 2002). Whereas HBD-1 and HBD-2 were monomeric in solution, HBD-3 was a dimer.

Structural studies on HBD-2 also revealed some structural similarities with MIP-3α/CCL20, a chemokine showing high affinity for CCR-6 (Perez-Canadillas et al. 2001). Both molecules have a rigid conformation of the N-terminal CC motif, as well as the narrow groove between the N-loop and the β2-β3 hairpin. Interestingly, HBD-2 also binds to CCR-6 and exhibits chemoattractant activity for dendritic cells.
Chapter 6  Defensins and Other Antimicrobial Peptides and Proteins

through its interaction with this chemokine receptor (Yang et al. 1999).

The θ-defensins, initially discovered in rhesus macaque neutrophils, have a remarkable structure, so far unique among mammalian peptides. These 18-amino acid (aa) peptides with three intramolecular disulfide bonds have a cyclic amide backbone (Tang et al. 1999; Leonova et al. 2001), formed from two nonapeptides by a novel posttranslational ligation reaction. The nonapeptides are encoded by two θ-defensin genes very similar to conventional α-defensins except that they are shortened by a “premature” stop codon, and contain only three cysteines. Either homodimers or heterodimers can be joined to form a mature θ-defensin peptide.

Structure and location of defensin genes

Many different defensin genes have been sequenced. The myeloid α-defensin (DEFA) genes have similar layouts, with three exons that correspond approximately to the 5′-untranslated region, signal sequence/propiece, and mature defensin region (Linzmeier et al. 1993). The genes for HD-5 and 6, α-defensins expressed predominantly within the intestine, have only two exons as do the DEFB genes that encode β-defensins, suggesting that the evolution of α-defensins involved both deletional and insertional events. Although dissimilar in their genomic sequence, the genes for HD-5 and HD-6 show considerable sequence similarity in their proximal 5′-flanking regions, which presumably contain elements involved in their tissue-specific expression (Mallow et al. 1996; Salzman et al. 2003). The DEFA genes encoding human myeloid and enteric α-defensins are clustered on human chromosome 8 (Linzmeier et al. 1999). The human DEFB genes that encode HBD-1, HDB-2, and HDB-3 contain two exons and are all within a few hundred kilobases from the myeloid α-defensin locus on chromosome 8p23 (Liu et al. 1997; Peng et al. 2001). This region is also home to a DEFT pseudogene that is highly homologous to the genes encoding the α-defensins of rhesus monkeys. θ-defensin (DEFT) genes evidently arose in an Old World monkey when the mutation of a preexisting α-defensin gene placed a premature stop codon within Exon 3 of a DEFA gene. Additional defensin and defensinlike genes have been identified in four other chromosomal loci, but their tissue expression and biology remain to be characterized (Schutte et al. 2002).

Activities of defensins

Gram-positive and gram-negative bacteria

A review of the antimicrobial activity of defensins against gram-positive and gram-negative bacteria is available (Lehrer et al. 1993). Briefly, defensins are effective broad-spectrum microbicides, especially when present in high local concentrations or acting in low-ionic strength media. High local concentrations occur within phagolysosomes, in the capillary-like lumen of small intestinal crypts, and at interfaces between effector and target cells.

Rabbit defensins NP-1 and NP-2 bind with high affinity to *Pseudomonas aeruginosa* PA01, forming small surface blebs and permeabilizing its outer membrane. This process, sometimes called “self-promoted uptake” (Sawyer et al. 1988), allows the polycationic peptide molecules to displace divalent cations that link adjacent lipopolysaccharide (LPS) molecules. The consequent permeability changes allow otherwise excluded molecules, such as lysozyme, to enter the periplasmic space and attack the bacterium further. Viljanen and coworkers (Viljanen et al. 1988) noted that human defensins increased the outer membrane’s permeability to hydrophobic probes (e.g., rifampin) in *P. aeruginosa*, *Escherichia coli*, and *Salmonella typhimurium*. Bactericidal concentrations of HNP-1 permeabilized the outer and inner membranes of *E. coli*, causing immediate and simultaneous cessation of macromolecular synthesis and respiration (Lehrer et al. 1989a).

Permeabilization of microbial cell membranes is a hallmark of defensin-mediated antimicrobial activity. Especially with human defensins, such permeabilization is prevented by treatments that inhibit the target cell’s metabolism, growth, or transmembrane protonmotive force (Lehrer et al. 1989a). Defensins permeabilize artificial phospholipid membranes only when a transmembrane electromotive force of sufficient magnitude and correct polarity is applied (Kagan et al. 1990). Membrane conductance increases as the second to fourth power of the defensin concentration, suggesting that two to four defensin molecules interact to form a channel in this system. Wimley and associates (Wimley et al. 1994) examined interactions between human defensins and lipid bilayers. They found that HNP-2 (net charge, +3) bound to and permeabilized unilamellar vesicles composed of anionic phospholipids, but not those formed of electroneutral phospholipids. Data from experiments with entrapped markers of
different sizes suggested that multimeric HNP-2 formed aqueous pores with a maximum diameter of ~25 Å. If such pores formed in bacterial membranes, they should allow passage of defensin monomers and even dimers (~26 × 15 × 15 Å) to more interior sites.

Certain bacteria are intrinsically resistant to defensins, including Neisseria gonorrhoeae (Qu et al. 1996a), Burkholderia cepacia, Burkholderia pseudomallei (Jones et al. 1996), and Brucella spp. (Martinez de Tejada et al. 1995). What can make bacteria resistant has been partially explained by identifying mutations that increase bacterial susceptibility to antimicrobial peptides. Studies on the intracellular enteric pathogen S.

typhimurium revealed the importance of the two-component regulatory system, PhoP/PhoQ. PhoQ is a magnesium-binding sensor kinase that responds to ionic and other environmental changes by phosphorylating PhoP, a DNA-binding protein that can activate numerous genes, including some needed for resistance to antimicrobial peptides and intracellular survival (Miller et al. 1990; Channongpol et al. 2003). These include important aspects of LPS structure (Ernst et al. 2001), and expression of an outer membrane protease that cleaves, and presumably inactivates, certain antimicrobial peptides (Guina et al. 2000).

Studies with Staphylococcus aureus associated its relative resistance to defensins and other cationic antimicrobial peptides to the modification of its membrane phospholipids with L-lysine (Kristian et al. 2003) and of its lipoteichoic acids with D-alanine (Collins et al. 2002). Both modifications reduce electrostatic binding of the peptides to the staphylococcal surface. N. gonorrhoeae may owe its defensin-resistance to an energy-dependent “mtr” efflux pump (Shafer et al. 1998). These findings suggest that interactions with cationic antimicrobial peptides may have profoundly influenced bacterial evolution.

In summary, the effect of defensins on microbes can be envisioned to occur in stages. Electrostatic adsorption to anionic sites on or near the target cell’s membrane or (for certain defensins) to sugars in microbial glycoproteins or LPS result in locally high concentrations that promote defensin aggregation and multimer formation. Insertion of defensins into microbial membranes is assisted by their positive charge and by the target cell’s transmembrane potential. The ensuing membrane disruption and channel formation permit intracytoplasmic entry of defensins and allow essential microbial components to leak out. Unless repaired, these events lead to irreversible target cell injury.

**Fungi**

Mammalian defensins can kill various fungal pathogens, including Candida spp., Cryptococcus neoformans, and hyphae and germinating spores of Rhizopus oryzae and Aspergillus fumigatus (reviewed in Lehrer et al. 1993). In recent years, the antifungal properties of defensins have been studied more by botanists and agriculturists than by immunologists. This reflects the importance of fungi as plant pathogens (Thomma et al. 2002) and the likely utility of transgenic plants. Plant defensins, like those of mammalian origin, probably owe their antifungal properties to an ability to induce membrane permeabilization (Thevissen et al. 1999).

**Mycobacteria, spirochetes, and protozoa**

Both human and rabbit defensins show activity against mycobacteria, including M. tuberculosis (Miyakawa et al. 1996; Sharma et al. 2000) and M. avium-intracellulare (Ogata et al. 1992), even in the presence of divalent cations or physiologic salt concentrations. Although the plasma membrane of M. tuberculosis is the principal target for HNP-1 action, its DNA may be a secondary target (Sharma and Khuller 2001). Human neutrophils can ingest and kill both M. avium (Hartmann et al. 2001) and M. tuberculosis, and the latter is apparently subdued by nonoxidative mechanisms (Kisch et al. 2002). In vivo, mycobacteria that evaded or survived the attentions of neutrophils would likely find a defensin-free sanctuary once resident within a macrophage, because the only mammalian macrophages known to contain significant quantities of defensins are alveolar macrophages of the rabbit.

In a rabbit model of syphilis, large local amounts of defensins were seen during the first 24 hours. This subsided, but reappeared on days 10 to 16, when healing began (Borenstein et al. 1991). The Nichols strain of Treponema pallidum was neutralized by rabbit defensins in vitro and in vivo. Borrelia burgdorferi, the causative agent of Lyme disease, is also susceptible to defensins (Lusitani et al. 2002).

The effect of defensins on protozoans has received little study, at least in vertebrates. Human α-defensin HNP-1, mouse Paneth cell defensin-2 and defensin-3 (cryptdins), and rabbit α-Defensin NP-2 killed trophozoites of Giardia lamblia, especially when the concentrations of sodium chloride and divalent cations were low (Aley et al. 1994).

**Antiviral properties**

Both α-defensins (Zhang et al. 2002) and θ-defensins (Cole et al. 2002) can protect cells from infection by HIV-1 in vitro. Persons infected with human immunodeficiency virus–1 (HIV-1) whose α,β CD8 T cells maintain the ability to produce and release α-defensins may exhibit relative resistance to developing acquired immune deficiency syndrome–defining (AIDS-defining) symptoms, compared with HIV-infected subjects whose T cells are defective in this regard (Zhang et al. 2002). θ-Defensins act by blocking an early step in the uptake process, and their ability to do so correlates with their ability to bind gp120 with high affinity (Cole et al. 2002). α-defensins also bind gp120 with high affinity, but their mechanisms of action against HIV-1 has not yet been defined.

α-Defensins also protect cells from infection by herpes simplex virus (HSV) types 1 and 2 in tissue culture media (Daher et al. 1986), by interfering with an early step in the infection process (Sinha et al. 2003). Human and rabbit α-defensins also neutralized vesicular stomatitis and influenza A/WSN virus, but lacked significant activity against cytomegalovirus, reovirus, and echovirus (Daher et al. 1986). Among the nonenveloped viruses, only adenoviruses
have so far been reported to be susceptible to defensins (Gropp et al. 1999; Bastian and Schafer 2001).

Cytotoxic activity

Purified human defensins kill various normal and tumor cell targets in a concentration and time-dependent fashion (reviewed in Lehrer et al. 1993) and show synergistic activity when combined with sublytic concentrations of hydrogen peroxide. Defensin molecules bound to mammalian target cells with biphasic kinetics, similar to those with Candida albicans. K562 cells exposed to 20 μg/ml of radiolabeled HNP-1 bound approximately 4.3 × 10⁶ defensin molecules per cell. This initial binding did not cause cytolysis and was comparable in defensin-resistant and defensin-sensitive target cells. After 5 to 10 minutes, sensitive targets became permeable to trypan blue (molecular weight = 960 Da) and manifested enhanced transmembrane ion flux. Membrane-bound defensin molecules became progressively more difficult to dislodge by adding serum, and after 3 to 4 hours, the cells began releasing ⁵¹Cr-labeled cytoplasmic components. Strand breaks and adenosine triphosphate–ribosylation (ADP-ribosylation) were first detected in K562 and Raji targets 6–8 hours after incubation with HNP, and these increased to maximal levels by 18 hours. DNA was not degraded into nucleosome-sized fragments. Other experiments suggested that the initial defensin-induced pores were voltage dependent and that defensin-mediated injury to mammalian cells depended on an energized target cell membrane. Since defensins are bound by α2-macroglobulin and other normal serum components, it is not surprising that defensins were minimally, if at all, cytotoxic in the presence of serum. Whether and where defensins are cytotoxic in vivo is not known.

Other properties of defensins

Although most studies of defensins have examined their antimicrobial properties, considerable evidence suggests that some defensins also play other roles, including immunomodulation, hormonal regulation, opsonization, and stimulating wound repair. Human neutrophil defensins are chemotactic for human monocytes (Territo et al. 1989), T-cells (Chertov et al. 1996), and immature dendritic cells (Yang et al. 2000) in vitro, so that their release from neutrophils could provide a signal to mobilize immunocompetent mononuclear cells. Defensins also induce the synthesis of interleukin-8 (IL-8), a C-X-C cytokine, by human airway epithelial cells, possibly providing a mechanism to recruit additional neutrophils to sites of inflammation (Van Wetering et al. 1997). The α-defensins of human neutrophils were shown to act as adjuvants to enhance systemic IgG antibody response (Lillard et al. 1999). Murine β-defensin MBD-2 acted as an adjuvant for tumor immunization, by providing a costimulatory signal via the toll-like receptor 4 (Biragyn et al. 2002). It is not yet clear whether these activities are shared by other defensins.

Rabbit NP-3a ("corticotatin") and certain other α-defensins bound reversibly to the adrenocorticotropic hormone (ACTH) receptor of rat adrenal cells in vitro and inhibited ACTH-stimulated steroidogenesis (Zhu and Solomon 1992). Rabbit defensins NP-1 and NP-2 greatly enhanced the ability of rabbit alveolar macrophages to ingest bacteria and fungi under serum-free conditions (Fleischmann et al. 1985). Defensins were mitogenic for fibroblasts (Murphy et al. 1993), and small daily injections of rabbit defensins accelerated wound healing in rats (Kudriashov et al. 1990). Guinea pig defensins were reported to release histamine from rat mast cells in vitro (Yamashita and Saito 1989).

DEFENSINS IN MYELOID CELLS

Role in mucosal host defense

Most normal mucosal surfaces contain considerably more epithelial cells than neutrophils or macrophages. Notable exceptions include the gingival crevices that surround teeth, which are bathed in high concentrations of neutrophils and their components. Neutrophil defensin concentrations as high as 1 mg/ml have been detected in such fluids (T. Ganz and K. Miyasaka, unpublished) and could play an important role in controlling local microbial proliferation.

In other locations, neutrophils and macrophages are rapidly recruited to epithelial surfaces when the primary mucosal defenses are overwhelmed by microbial invaders. The important function of these secondary defenses is illustrated by the particularly severe impact of neutropenia on the integrity of oral and gastrointestinal mucosae and the characteristic involvement of periodontal tissues in congenital or acquired neutrophil disorders.

Cellular localization of myeloid defensins

Each human neutrophil contains several thousand cytoplasmic granules that are divided into three principal subtypes, called primary (or azurophil), secondary (or specific), and tertiary. These subtypes can be distinguished by buoyant density, when they are made during the neutrophil’s maturation, their response to secretagogues, and their composition. About 30% to 50% of the protein content of the azurophil granules consists of defensins. Relatively small amounts of defensins are released extracellularly after phagocytosis or secretagogue exposure, as the peptides are preferentially delivered phagosomes that contain opsonized bacteria (JOINER et al. 1989). This targeted delivery of defensins not only places them where they are most needed, but it also helps minimize any potential cytotoxicity to host tissues. The high concentrations of defensins in human neutrophils are not unique: α-defensins are similarly plentiful in the granules of rabbit neutrophils (~10–15 μg/million cells) and rabbit alveolar macrophages (~2 μg/million cells). Although myeloid defensins (HNPs) 1–4 are most abundant in neutrophils, HNP-1 is also highly expressed by natural killer (NK) cells (OBATA-ONAI et al. 2002; AGERBERTH et al. 2000) and can be produced by other lymphocytes (AGERBERTH et al. 2000).
Structure and production of myeloid defensin precursors

Although human blood neutrophils contain about 5 μg of defensins per million cells, defensin mRNA is not detectable in Northern blots of mature neutrophils, indicating that defensin synthesis is restricted to the neutrophil’s bone marrow precursors. Myeloid α-defensins are synthesized as 90–95-aa prepropeptides with a generally well-conserved signal sequence, followed by an anionic propiece and the C-terminally placed defensin domain. Nevertheless, nearly all of the defensin in neutrophil azurophil granules is found to be completely processed to 29–30-aa mature peptides (Harwig et al. 1992).

Posttranslational defensin processing has been studied in metabolically labeled HL-60 and CML cells (Valore and Ganz 1992). Their earliest defensin intermediate contained 75 aa and arose by cotranslational removal of the 19-residue signal sequence. Considerable quantities of this 75-aa form were secreted into the medium, and the remainder was proteolytically processed over 20 hours via a 56-aa intermediate into the mature 29-aa and 30-aa defensins. Mature human neutrophils also contained minor amounts (0.25% of total defensins) of incompletely processed 39-aa, 34-aa, and 32-aa defensins (Harwig and Ganz 1992).

This pattern of synthesis and posttranslational processing was substantially reproduced when the HNP-1 defensin cDNA was transduced into defensinless murine 32D and 32D cl3 cells (Liu and Ganz 1995). These transgenic lines accumulated mature defensin in acidified vacuoles corresponding to lysosomes or immature granules. In contrast, two transgenic, defensin-producing nonmyeloid cell lines (an embryonic NIH 3T3 cell line and the pituitary adenoma cell line ArT-20) failed to process the 75-aa prodefensin, indicating that the requisite processing pathway may be tissue specific.

To study the role of the propiece in preproHNP-1, a series of in-frame deletions between the signal peptide site and the aminoterminus of the mature defensin region (aa 21–64) was constructed, packaged, and transduced into the 32D cl3 granulocytic cell line. Deletions in the aminoterminal two-fifths of the propiece had only minor effects on defensin biosynthesis and did not interfere with accumulation of mature defensin in the granules of 32D cl3 cells. Deletions in the carboxyterminal three-fifths of the propiece diminished net defensin synthesis, blocked constitutive secretion of prodefensin, and interfered with defensin accumulation in cytoplasmic granules. These effects were reproduced by the smaller deletion Δ40–51, which contains a highly conserved secondary structure. Therefore, propiece residues 40–51 appear to be essential for subcellular trafficking and sorting of human neutrophil α-defensins (Liu and Ganz 1995).

β-defensins in animal leukocytes

Instead of containing α-defensins like those found in human, rabbit, rat, hamster, and guinea pig neutrophils, bovine neutrophils contain an impressive array of β-defensin peptides (Selsted et al. 1993). Whereas myeloid α-defensins have free amino termini, about half of the β-defensins isolated from bovine neutrophils had a pyroglutamate residue at their amino terminus. This moiety characteristically results from enzymatic modification of an amino-terminal glutamine residue and could confer resistance to proteolytic cleavage by local proteases or alter other biologic properties. The β-defensin peptides from neutrophils manifest antibacterial activity against gram-positive and gram-negative bacteria, but because different in vitro assay conditions were used, direct comparison of the relative activity of bovine epithelial and neutrophil β-defensins is not yet possible.

β-defensins ("gallinacins") were also isolated from the leukocytes of chickens (Harwig et al. 1994) and turkeys (Evans et al. 1994). Two of the three chicken gallinacins differed at only three amino-acid residues and had comparable antibacterial and antifungal activities. The third gallinacin differed at over half of the amino acids and exerted antibacterial activity, but lacked the antifungal activity seen with the other two (Harwig et al. 1994). The β-defensins of turkeys showed good activity against C. albicans, Salm. enteriditis, and Campylobacter jejuni, but were relatively ineffective against Pasteurella multocida at 16 μg/ml, the highest peptide concentration tested. They did not neutralize infectious bronchitis virus, an enveloped coronavirus (Evans et al. 1995). In normal chickens, the expression of gallinacin-3 was especially prominent in the tongue, bursa of Fabricius, and trachea. It also occurred in other organs, including skin, esophagus, air sacs, large intestine, and kidney. The tracheal expression of gallinacin-3 increased significantly in chickens experimentally infected with H. paragallinarum (Zhao et al. 2001).

α-DEFENSINS IN ENTERIC PANETH CELLS

Role of endogenous intestinal antibiotics

Despite continual entry of microorganisms from swallowed food and oral secretions, the normal small intestine contains only a sparse resident flora. Why? Although multiple factors contribute, the ability of intestinal enterocytes and Paneth cells to secrete antimicrobial molecules is likely to play a significant role. Through their differential antimicrobial activities, these molecules could contribute to selecting the normal intestinal flora, which may afford protection from pathogenic bacteria that enter the intestine. Since the intestinal epithelium stem cells reside in the intestinal crypts, secretion of Paneth cell defensins into the crypt lumen (Figure 6.3) could provide a protective barrier for this vital proliferative compartment.

Identification of enteric α-defensins in Paneth cells

Paneth cells, first described over 100 years ago, are located at the base of the crypts of Lieberkühn. They are more abundant in the region of the ileum and jejunum and less so in the duodenum. The high density of Paneth cells in the distal
small intestine might signify a role in preventing adverse con-
sequences from reflux of colonic flora into the ileum. Paneth
cells contain an extensive endoplasmic reticulum and Golgi
network and are filled with numerous, apically located
eosinophilic secretory granules whose secretion is stimulated
by cholinergic agonists or the entry of bacteria or
lipopolysaccharide (Satoh 1988; Qu et al. 1996b).

Ouellette and colleagues (Ouellette et al. 1989) identified
an α-defensin among several prominently expressed RNA
messages in the postnatal mouse small intestine. Because this
mRNA was expressed in Paneth cells at the base of small
intestinal crypts, the corresponding peptides were named
“cryptdins.” Cryptdin mRNA levels were normal in
germfree and nude mice, suggesting that expression was
independent of T-cell signals or acquisition of the intestinal
flora. Independently, two α-defensin genes (HD-5 and
HD-6) expressed in human Paneth cells were detected (Jones
and Bevins 1992, 1993). In contrast to the six characterized
murine enteric defensin genes, which had very high (85%)
nucleotide similarity, HD-5 and HD-6 were not as closely
related, presumably having duplicated and diverged before
their murine counterparts (Bevins et al. 1996). The striking
difference in murine and human enteric defensin gene num-
bers remains enigmatic. Paneth cells also secrete larger
antimicrobial polypeptides, including lysozyme and secre-
tory phospholipase A2 (see sections on “Identification of
enteric α-defensins in Paneth cells” and “Developmental
regulation of enteric α-defensin expression” in this chapter).

Antimicrobial activity of enteric α-defensins
Native mature defensins (cryptdins) have antibacterial and
activity comparable with myeloid defensins (Selsted et al.
1992; Eisenhauer et al. 1992) and can kill the protozoan para-
site Giardia lamblia (Aley et al. 1994). Recombinant human
small intestinal defensin HD-5 was effective against Listeria
monocytogenes, S. typhimurium, and C. albicans (Porter
et al. 1997b; Ghosh et al. 2002). It showed minimal cytotoxic
activity against human intestinal cell lines (Porter et al.
1997a).

Developmental regulation of enteric α-defensin
expression
Morphologically identifiable Paneth cells appear in the
mouse intestine immediately before birth. Thereafter,
murine α-defensin mRNA levels and defensin immunoreac-
tivity increase gradually and reach adult levels by the fourth
postnatal week, paralleling expansion of the Paneth cell pop-
ulation. Mice reared in a germfree environment express
comparable levels of enteric α-defensins (Ouellette et al.
1989; Putsep et al. 2000). In humans, a sensitive RT-PCR
assay can detect mRNA encoding human enteric defensins
HD-5 and HD-6 at 13.5 weeks’ gestation, close to the time
that morphologically distinguishable Paneth cells can be
identified by electron microscopy. At approximately 24
weeks’ gestation, HD-5 and HD-6 mRNA was detected in
Paneth cells of the small intestinal crypt by in situ hybridiza-
tion. By Northern blot analysis, the levels were approxi-
mately 100-fold lower than in adults. The ability to detect
human enteric defensin mRNA prenatally indicates that its
expression is at least partially constitutive and governed by a
developmental program that operates without direct stimula-
tion by microbes or their products.

Like their hematopoietic counterparts, intestinal α-
defensins are initially synthesized as propeptides.
However, unlike the myeloid defensins, Paneth cell defensins
are stored as propeptides, exclusively so in humans (Porter
et al. 1998; Ouellette et al. 2000; Ghosh et al. 2002). The post-
translational processing of these epithelial α-defensins
appears to be an important regulatory step in the generation
of bioactive peptides in the small intestine. However, the
pathways of processing appear to be quite different in
mice and humans. In mice, the matrix metalloprotease
matrilysin (matrix metalloproteinase 7) has been identified as

Fig. 6.3. Human small intestine, immunostained for HD-5. A longitudi-
inally cut tubular crypt is prominent and contains several Paneth
cells (PC) that contain numerous large, immunoreactive granules
(asterisks). The intestinal lumen and the lamina propria (LP) have been
labeled. Reproduced from Porter et al. (1997a) with permission.
an essential enzyme in the processing of small intestinal α-defensins (Wilson et al. 1999). In humans, the orthologous small intestine α-defensins are processed to mature peptides during or after secretion into the small intestinal lumen by the serine protease trypsin (Ghosh et al. 2002). In both species, the proteases mediating this α-defensin processing are expressed by Paneth cells.

The role of Paneth cell defensins

The hypothesis that intestinal defensins contribute to the regulation of microbial flora in the small intestine received support from studies in matrilysin-deficient mice. Matrilysin (matrix metalloproteinase 7) is expressed specifically in Paneth cells. In mice with a targeted disruption of the intestinal prodefensin-processing protease, matrilysin, Paneth cell defensin precursors were not processed to active mature peptides. The mice had increased susceptibility to intestinal infections with gram-negative organisms (Wilson et al. 1999). Detailed analysis of secretions from the isolated crypts of normal and matrilysin-deficient mice indicated that the antimicrobial activity of crypt secretions was largely the result of defensins and that it was greatly impaired in matrilysin-deficient mice (Ayabe et al. 2000).

In another model, the transgenic expression of human defensin-5 in the Paneth cells of mice increased their resistance to orally administered S. typhimurium but, as might be expected, did not protect against infection by the peritoneal route (Saltzman et al., 2003). In the aggregate, these models point to a central role for Paneth cell defensins as regulators of small intestinal flora and as enteroprotective molecules.

EPITHELIAL β-DEFENSINS

Bovine “tracheal antimicrobial peptide” (TAP) and other animal β-defensins

Bovine tracheal extracts contain an abundant peptide called “TAP,” or tracheal antimicrobial peptide, that exhibited antimicrobial activity in vitro against Klebsiella pneumoniae, S. aureus, and C. albicans (Diamond et al. 1991). Sequence analysis revealed similarity of this molecule to defensins expressed in leukocytes and to its designation as the first epithelial β-defensin. TAP expression was found in the pseudostratified columnar epithelial cells of conducting airway and nasal mucosa (Diamond et al. 1993). A hallmark of TAP expression, like several more recently described epithelial β-defensins of humans and mice, is inducible expression in response to bacterial LPS and some inflammatory cytokines (Diamond et al. 1996; Russell et al. 1996; Diamond et al. 2000). A canonical NF-κB recognition site in the 5′-flanking region of the TAP gene was important in the transcriptional regulation of this gene by bacterial products (Diamond et al. 2000). In vivo inoculation of pathogenic bacteria into the bovine lung caused a rapid and dramatic increase in β-defensin expression in the conducting airway epithelium, which was not seen in the adjacent control lobe (Stolzenberg et al. 1997).

In bovine tracheal epithelial cells, β-defensin induction by LPS appears to be dependent on epithelium-derived CD14, a well-characterized LPS-binding protein (Diamond et al. 1996). This suggests that local expression of CD-14 might provide epithelial cells with the capacity to recognize bacterial products at mucosal surfaces and initiate local defense responses such as antimicrobial peptide production.

Several additional sites of β-defensin expression were identified in cattle, including squamous epithelial cells of the tongue (Schonwetter et al. 1995) and epithelial cells of the small intestine and colon (Tarver et al. 1998). mRNA encoding a bovine lingual β-defensin (“LAP”) was markedly increased in epithelia surrounding naturally occurring tongue lesions, suggesting an integral role for antimicrobial peptides in local inflammatory responses. The antimicrobial activity of LAP and TAP was very similar, and LAP expression was enhanced in bovine trachea after LPS or TNF-α application (Russell et al. 1996). In mice, epithelial expression of β-defensins is also observed in the mucosal epithelium of the respiratory and digestive tracts (Morrison et al. 1999; Bals et al. 1999; Jia et al. 2000).

Similar to humans, mice express a noninducible β-defensin in kidney tubule cells and mucosal epithelia of several organ systems (Huttner et al. 1997). Recent studies of mice rendered deficient in this epithelial β-defensin through targeted homologous recombination have shown a minimal phenotype (Moser et al. 2002; Morrison et al. 2002). Further studies of these mice may be necessary to elucidate the functional role of this β-defensin.

Human epithelial β-defensins

A systematic characterization of the peptides present in human blood ultrafiltrates provided the first evidence for the existence of HBD-1, the first characterized human β-defensin (Bensch et al. 1995). HBD-1 shared the nine invariantly conserved amino acids present in β-defensins from bovine and avian cells. Although free HBD-1 was present in nanomolar concentrations in human plasma, an abundant HBD-1 message occurred in the kidney and vagina (Bensch et al. 1995). Several HBD-1 peptides, generated by differential posttranslational proteolysis at the N-terminus, were the predominant cationic peptides in urine. When tested, using urine as a growth medium, they displayed antibacterial activity against E. coli. In situ hybridization and immunostaining localized their site of production to the distal tubules of the kidney as well as the various epithelia of the female genital tract (Valore et al. 1998).

HBD-1 is also present in human conducting-airway epithelia (McCray and Bentley 1997) as well as in epithelia of many other tissues and in certain glands (Zhao et al. 1996). Expression of HBD-1 by lung epithelia is developmentally regulated, in a manner reminiscent of the α-defensins found in rabbit lung macrophages (McCray and Bentley 1997). Circumstantial evidence implicates the impaired function of HBD-1, consequent to high bronchial fluid salinity (Smith et al. 1996), as a contributing factor in respiratory tract colonization by P. aeruginosa in cystic fibrosis patients (Goldman et al. 1997).
**Chapter 6  Defensins and Other Antimicrobial Peptides and Proteins**

*HBD-2* was first detected as an abundant cationic peptide and an antimicrobial component in the flaking epidermis of patients with psoriasis (Harder *et al.* 1997). It is produced by differentiated keratinocytes in the epidermis under the influence of inflammatory signals, principally IL-1 (Liu *et al.* 1998, 2002, 2003) and secreted in lamellar bodies into the space between keratinocytes, along with the lipids that make the epidermis impermeable to water (Oren *et al.*, 2003). There, *HBD-2* reaches concentrations sufficient for antimicrobial activity (Liu *et al.* 2002). *HBD-2* is active against a broad range of microbes, with the significant exception of the skin pathogen *S. aureus* (Harder *et al.* 1997; Liu *et al.* 2002).

*HBD-3* was detected more or less simultaneously by genomic methodologies (Jia *et al.* 2001; Garcia *et al.* 2001a) and by direct extraction of the peptide from psoriatic skin (Harder *et al.* 2001). *HBD-3* is one of the most cationic defensins known, with a charge of +11 at neutral pH. Unlike *HBD-2*, *HBD-3* is active against *S. aureus* and even *B. cepacia*, at least under low ionic strength conditions. The skin and the tonsils appear to have the highest levels of expression, but *HBD-3* is detectable in other epithelial and nonepithelial tissues as well. The mechanisms of its regulation have not yet been reported.

Genomic analysis indicates that many additional human β-defensin genes and related genes exist, but they remain to be characterized at the peptide level (Schutte *et al.* 2002).

**EVOLUTIONARY CONSIDERATIONS**

The α-defensin and β-defensin families almost certainly arose by divergence from an ancestral pre mammalian defensin and not by convergent evolution. This conclusion is supported by the proximity of human α-defensin and β-defensin genes within 150 kb on chromosome 8p23 (Liu *et al.* 1997). Defensinlike molecules not assignable to either defensin family have been identified in invertebrates. Hemocytes of the horseshoe crab, *Tachypleus tridentatus*, contain an antibacterial peptide ("big defensin") whose C-terminal 37 residues have a cysteine structure resembling that of mammalian β-defensins and a primary sequence similar to rat myeloid α-defensins (Saito *et al.* 1995). When the unusually long, 35-residue amino-terminal extension of big-defensin was cleaved by trypptic digestion, both the defensinlike domain and the amino-terminal extension had antimicrobial properties. An extremely defensinlike antiviral peptide was also identified in the sea anemone, *Anemonia sulcata* (Driscoll *et al.* 1989).

The primary structural resemblance between avian β-defensins (gallinacins) and certain cytostatic (Marquardt *et al.* 1988) and myotoxic peptides in snake venoms (Fig. 6.4) also suggests that the progenitors of β-defensins had potential to become weapons of offense, as well as of host defense. The same can be said about the antimicrobial insect defensins, which show striking structural similarity to certain toxic peptides found in scorpion venom (Cociancich *et al.* 1993).

Given such findings, it is reasonable to postulate the antiquity of defensins as host-defense molecules. An evolutionary relationship between vertebrate defensins and the structurally more distant defensins of insects and plants is possible, but lacks convincing supporting data.

**OTHER MUCOSAL DEFENSE MOLECULES**

**Calprotectin**

Calprotectin, a member of the widespread calcium-binding S-100 protein family, is present in remarkably high concentration in the cytoplasm of human neutrophils (Brandtzæg *et al.* 1995). The calprotectin molecule is composed of light (MRP8) and heavy (MRP14) subunits. Although not secreted from intact neutrophils, calprotectin release from dead and dying neutrophils creates high concentrations of the protein in inflammatory or abscess fluids and in the intestinal tract lumen of patients with inflammatory bowel disease. Calprotectin is also found in reactive tissue macrophages, in nonkeratinizing squamous epithelia, and in reactive epidermal cells. The C-terminal portion of calprotectin's heavy chain, MRP14, is identical to a peptide called neutrophil immobilizing factor, "NIF." Calprotectin concentrations of 50–250 μg/ml inhibit growth by *S. aureus*, *S. epidermidis*, and *E. coli*. Even lower concentrations (4–32 μg/ml) inhibit growth by *C. albicans*, possibly by depriving the Candida cells of zinc. Calprotectin purified from rat inflammatory peritoneal cells was markedly cytotoxic for mitogen-stimulated lymphocytes and for various tumor cell lines, in

![Fig. 6.4](image-url) From serpent's tooth to chicken soup. Myotoxin A is a myotoxic peptide from the venom of *Crotalus viridis viridis*, the prairie rattlesnake (Fox *et al.* 1979). SVGAP stands for snake venom growth arresting peptide (Marquardt 1988), and is described in U.S. patent 4774318. Cal-1 is the chicken β-defensin gallinacin-1, originally isolated from chicken heterophils (Harwig *et al.*, 1994) and later found in chicken soup (Lehrer unpublished). The disulfide pairing patterns (1:5, 2:4, 3:6) of myotoxin A (Fox *et al.* 1979) and avian β-defensins (Harwig, unpublished) are identical.
which it induced apoptosis. Epithelial cell calprotectin might protect host cells from microbes that invade the cytoplasm directly or by lysing phagosomal membranes.

The murine MRP8 protein (also called CP10 or S100A8) is chemotactic for myeloid cells but this property is not shared by human calprotectin. Homozygous disruption of MRP8 (S100A8) gene in mice causes embryonic death by day 9.5 but MRP14 (S100A9)-deficient mice are viable and healthy (Manitz et al. 2003) even though their neutrophils lack both MRP8/14 partners. Initial studies of these mice detected only very mild defects in neutrophil cytoskeletal organization and migration, but the activity of these neutrophils in microbicidal assays has not been reported.

**Lysozyme (muramidase)**

Lysozyme was discovered over 75 years ago by Fleming, who called it a “remarkable bacteriolytic ferment” and did not patent it—or penicillin, which he discovered a few years later. This very cationic 14.3-kDa protein enzymatically attacks the β1-4 glycosidic bonds between N-acetylglucosamine and N-acetylmuramic acid, which stabilize bacterial peptidoglycans. Gram-positive bacteria susceptible to the lytic action of lysozyme include Bacillus subtilis, Bacillus megaterium, and Micrococcus luteus (see lysodeiticus). Lysozyme also exerts bactericidal activity by nonenzymatic, nonbactericidal mechanisms. It is a remarkably abundant component of phagocytic leukocytes, and also of tears, saliva, and many other secretions. The detection of abundant lysozyme in Paneth cell granules yielded the first clue that these intestinal epithelial cells were important in host defense (Peeters and Vantrappen 1975). Most gram-negative bacteria are resistant to lysozyme, except under very low ionic strength conditions. This is caused largely by the protective effects of their outer membrane, which covers and masks their peptidoglycan layer. Lysozyme may function most effectively in conjunction with other antimicrobial factors, especially those capable of permeabilizing the outer membrane.

Recent experiments in mice deficient in lysozyme-M (Ganz et al., 2003) showed delayed killing of the lysozyme-sensitive *M. luteus*, but the major abnormality in these mice was the highly exaggerated inflammatory response to these bacteria and to peptidoglycan. Peptidoglycan is a potent inflammatory stimulus, in part through its binding to TLR-2 and by peptidoglycan recognition proteins. Whatever lysozyme may contribute to antibacterial activity, it appears to be critically important for eliminating bacterial peptidoglycan, thus extinguishing the strong signal to innate immunity and inflammation generated by this characteristic bacterial macromolecule.

**Lactoferrin**

Lactoferrin is a 78-kDa single-chain glycoprotein that can bind one or two molecules of ferric iron. It is found in various secretions, including tears, milk, and semen, and also in the secretory granules of neutrophils. Intestinal cells and mononuclear phagocytes have surface receptors for lactoferrin, but do not synthesize it. Certain bacteria (e.g., *N. gonorrhoeae*, *Neisseria meningitidis*, and *Moraxella catarrhalis*) also possess lactoferrin receptors and use them to acquire iron. Lactoferrin or lactoferricin-treated gram-negative bacteria release LPS, develop electron-dense “membrane blisters,” and become sensitized to lysozyme—all consistent with outer membrane damage. Lactoferrin binds bacterial lipopolysaccharide with high affinity and also binds various other proteins. Exposure of lactoferrin to pepsin (its normal fate when ingested in milk) releases an antimicrobial polypeptide, “lactoferricin” comprising the amino-terminal lactoferrin residues (Tomita et al. 1994). Lactoferricin kills many bacteria and *C. albicans*, but is ineffective against *Proteus* and *Serratia* species and *P. cepacia*. Lactoferrin also inhibits microbial adherence to and invasion of epithelial cells.

Lactoferrin has a higher affinity for iron than its plasma homolog transferrin, and its iron binding is less affected by acid pH. These characteristics may allow it to function as an iron-sequestering substance in mucosal secretions and inflammatory fluids. Because iron is an essential metal for all living organisms, sequestration of iron is an effective means of inhibiting microbial growth. Iron starvation also interferes with bacterial biofilm formation. Even under conditions that otherwise promote biofilm formation, lactoferrin-exposed bacteria remain in the planktonic form, presumably allowing the more mobile bacterial population to disperse and reach iron sources (Singh et al. 2002).

**Secretory phospholipase A₄ (sPLA₂)**

Phospholipase A₂ enzymes remove fatty acids from the middle (sn-2) carbon atom of phosphoglycerides. Several phospholipase A₂ enzymes occur in mammalian cells, but only the 14-kDa secretory PLA₂ (sPLA₂) has potent microbicidal properties, principally against gram-positive bacteria (Harwig et al. 1995; Weinrauch et al. 1996). sPLA₂ differs from pancreatic PLA₂ structurally and in preferring phospholipids prominent in bacterial membranes [e.g., phosphatidylglycerol (PG) and phosphatidylethanolamine (PE)] over phosphatidylcholine as substrates. PLA₂ is present in granules of human neutrophils and small intestinal Paneth cells. sPLA₂ is released from neutrophils exposed to secretagogues, such as phorbol esters or calcium ionophores, and by Paneth cells exposed to cholinergic agonists, bacteria, or LPS. Serum sPLA₂ levels are greatly elevated in patients with sepsis and rise sharply within 3 hours after the experimental administration of lipopolysaccharide to uninfected patients. High concentrations of sPLA₂ are also present in human tears. The antimicrobial specialization of this phospholipase is probably a result of its unusually high net positive charge and a cluster of positively charged residues near its N-terminus that facilitate its interaction with bacteria and access to its phospholipid target (Weiss et al. 1991).

**Proteinase inhibitors**

SLPI is a 107-aa (12.7-kDa) nonglycosylated peptide with a bipartite structure. It is very abundant in many human secretions, including seminal plasma, cervical mucus, nasal
secretions, and tears. SLPI has received many alternative names, including human seminal plasma inhibitor-I (HUSI-I), cervix uteri secretion inhibitor (CUSI), bronchial secretory inhibitor (BSI), and bronchial mucus inhibitor (MPI). Mice deficient in SLPI show impaired wound healing (Ashcroft et al. 2000; Zhu et al. 2002), but their response to infection has not been reported yet. In vitro, SLPI shows low-level activity against bacteria and fungi (Hiemstra 2002) and may also have anti-HIV activity. If the high concentrations of SLPI in many epithelial secretions compensate for its low intrinsic potency, its antimicrobial activity could be biologically important.

SLPI is synthesized as a 132-aa prepropeptide with a 25-aa signal peptide. Each of its two structurally similar domains contains four intradomain disulfide bonds in the “four-disulfide-core” pattern also present in wheat germ agglutinin and neurophysin. The C-terminal domain of SLPI (residues 55–107) shows homology to the second domain of chelatin, a basic protease inhibitor from Red Sea turtle, and is responsible for the molecule’s prominent antiprotease activity (Masuda et al. 1995). SLPI holoprotein and its N-terminal domain (residues 1–54) have microbialic properties (Hiemstra et al. 1996). Other protease inhibitors with antimicrobial properties include aprotinin, a 58-aa protease inhibitor in bovine mast cells (Pellegrini et al. 1996), and ENAP-2, a four-disulfide core protein found in equine granulocytes (Couto et al. 1992). Multifunctionality may be a common attribute of other proteins involved in host defense.

Antimicrobial ribonucleases

Eosinophils, as well as other myeloid and epithelial cells, contain cationic antimicrobial proteins belonging to the ribonuclease family (Rosenberg and Domachowski 2001). In humans, eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN) are among the principal components of eosinophil granules. ECP is broadly antimicrobial (Lehrer, 1989b) and toxic to helminths (Hamann et al. 1987, 1990), but EDN is nearly inactive in these assays. Both ECP and EDN show antiviral activity (Rosenberg and Domachowski 2001) against respiratory RNA viruses: respiratory syncytial virus (RSV) and a related murine virus. New members of the antimicrobial ribonuclease family likely to be important in defending body surfaces include RNase 7, an abundant component of human epidermis (Harder and Schröder 2002) and angiogenin 4, an antimicrobial protein of murine Paneth cell granules (Hooper et al. 2003). The specific role of these proteins in host defense remains to be defined.

BPI

Bactericidal permeability-increasing protein (BPI) (Elsbach and Weiss 1998) is found in the azurophil (primary) granules of human and rabbit neutrophils, but like defensins, may be absent from mouse neutrophils. It is a 55-kDa cationic protein and a member of a family of lipid-binding proteins, two of which, BPI and lipopolysaccharide-binding protein (LBP) avidly bind to bacterial lipopolysaccharide. In vitro, BPI is specifically active against selected gram-negative bacteria at concentrations as low as nanomolar, and this activity is wholly contained in a 25-kDa amino terminal fragment. The mechanism of activity of BPI against bacteria depends on the initial high-affinity interaction with LPS in the outer membrane. The resulting rapid permeabilization of the outer membrane is followed by a slower process that culminates in the disruption of the inner membrane of gram-negative bacteria with attendant loss of viability (Wiese et al. 1997). More recently, BPI was also identified as a component of human eosinophil granules and as a lipoxin-inducible protein in mucusal epithelia (Canny et al. 2002). In vitro studies suggest that BPI contributes to the killing of gram-negative bacteria in isolated epithelia and neutrophils.

Cathelin-associated peptides (“cathelicidins”)

The neutrophils of humans, pigs, cattle, sheep, mice, and other mammals contain a variety of structurally diverse antimicrobial peptides collectively called “cathelicidins.” These peptides were grouped together because they are synthesized at the carboxy-terminal portion of a precursor containing a highly conserved domain, approximately 100 amino acids long, called “cathelin” (Zanetti et al. 1995; Ganz and Weiss 1997). Some of these peptides have amphipathic α-helical structures, others form compact, defensin-like β-sheets stabilized by intramolecular cystine disulfide bonds, and still others are remarkably rich in proline, arginine, or tryptophan residues. The genes for cathelicidins contain four exons, the first three of which encode most of the conserved cathelin domain. Exon 4 specifies the last few cathelin residues, including the cleavage site and the mature peptide. The 5′ flanking sequences of this gene family contain motifs for binding NF-κB, IL-6, GM-CSF, and NF-1, suggesting that synthesis responds to mediators generated early during infection.

The sole known human cathelicidin is named hCAP18 or FALL39/LL37 (Agerberth et al. 1995; Cowland et al. 1995; Larrick et al. 1995). Unlike defensins, which are fully processed before they are stored in the azurophil granules of the neutrophil, the human cathelicidin peptide is stored in the specific (secretory) granules as hCAP18, a cathelin-containing, 140-residue, 17-kD propeptide. During or after secretion, hCAP18 undergoes proteolytic processing by propeptidas 3 (Sorensen et al. 2001) to liberate LL-37, the 37-residue, α-helical antimicrobial peptide at its C-terminus (Gudmundsson et al. 1996). The analogous proteolytic processing of bovine cathelicidins (proBac5 and proBac7) and porcine cathelicidins (proprotogersins 1–3) is mediated by trace amounts of neutrophil elastase (Panyutich et al. 1997; Scocchi et al. 1992).

mRNA for hCAP18 is found in testis (Malm et al. 2000), inflamed keratinocytes (Fromh et al. 1997; Agerberth et al. 1995), and airway epithelia (Bals et al. 1998). In vitro, LL-37 displayed both LPS binding (Hirata et al. 1995) and microbicidal activities (Agerberth et al. 1995) against E. coli. The abundance of LL-37 in neutrophil specific granules is about a third that of lactoferrin or lysozyme, the principal proteins of specific granules (Borregaard et al. 1995).

In addition to microbicidal activity, certain cathelicidins also have chemoattractant activity. For example, the human
cathelicidin LL-37 is chemotactic for neutrophils, monocytes, and T cells, but not for dendritic cells. This activity is likely mediated through binding to the formyl-peptide receptor-like 1 receptor (De et al. 2000). The proline-rich porcine cathelicidin PR-39 can induce upregulation of syndecans, heparan sulfate proteoglycans involved in the repair process at the site of skin wounds (Gallo et al. 1994).

Although the pig has a large number of cathelicidin genes, the most active antimicrobial peptides in porcine skin wounds are protegrins, secreted from neutrophils as proprotegrins and activated by proteolytic cleavage by neutrophil elastase (Panyutich et al. 1997). In vitro, inhibition of neutrophil elastase by specific inhibitors blocked the conversion of proprotegrins to protegrins and largely ablated the stable antimicrobial activity secreted by porcine neutrophils (Shi and Ganz 1998). The application of neutrophil elastase inhibitor to porcine wounds decreased the concentration of mature protegrin in wound fluid and impaired the clearance of bacteria from wounds. The deficit could be restored by supplementing the wound fluid with synthetic protegrin in vitro or in vivo (Cole et al. 2001). Thus protegrins act as natural antibiotics that contribute to the clearance of microbes from wounds.

Strong evidence for the antibacterial function of cathelicidins in the skin comes from studies of dermal infections in mice with an ablated gene for CRAMP (cathelin-related antimicrobial peptide). CRAMP, normally the main murine cathelicidin (Nizet et al. 2001), is the murine homolog of human hCAP18. In CRAMP-knockout mice, the skin lesions caused by experimental Group A Streptococcus inoculation were larger lesions and had higher numbers of viable bacteria than those seen in control mice. As in pigs, infiltrating neutrophils appeared to be the chief source of cathelicidins in inflamed skin. Epithelial cells also produced cathelicidins, but it is not clear if their production was quantitatively significant. How or if epithelial cathelicidins undergo proteolytic processing remains to be defined.

ACKNOWLEDGMENTS

Many of our previous and ongoing studies have been supported by grants from the National Institutes of Health, including: AI 32234, 32738, and 50843 to C. B.; AI 37945 and 32738 to C. L.; and HL46809, AI46514, and AI48167 to T. G. The continuing support of the Will Rogers Institute is gratefully acknowledged. We thank Ken Miyasaki for his artistic rendering of the human defensin dimer, all our past and present collaborators for putting up with us, and antimicrobial peptides for being there.

REFERENCES

Agerberth, B., Gunne, H., Odberg, J., Kogner, P., Boman, H. G., and Gudmundsson, G. H. (1995). FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc. Natl. Acad. Sci. USA 92, 195–199.

Agerberth, B., Charo, J., Werr, J., Olsson, B., Idali, P., Lindbom, L., Kiessling, R., Jornvall, H., Wizigl, H., and Gudmundsson, G. H. (2000). The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 96: 3086–3093.

Aley, S. B., Zimmerman, M., Hetsko, M., Selsted, M. E., and Gillin, F. D. (1994). Killing of Giardia lamblia by cryptdins and cationic neutrophil peptides. Infect. Immun. 62, 5397–5403.

Ashcroft, G. S., Lei, K., Jin, W., Longenecker, G., Kulkarni, A. B., Greenwell-Wild, T., Hale-Donze, H., McGrady, G., Song, X. Y., and Wahl, S. M. (2000). Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat. Med. 6, 1147–1153.

Ayabe, T., Satchell, D. P., Wilson, C. L., Parks, W. C., Selsted, M. E., and Ouellette, A. J. (2000). Secretion of microbialcidal α-defensins by intestinal Paneth cells in response to bacteria. Nat. Immunol. 1, 113–118.

Bals, R., Wang, X., Zasloff, M., and Wilson, J. M. (1998). The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc. Natl. Acad. Sci. USA 95, 9541–9546.

Bals, R., Wang, X., Meegalla, R. L., Watters, S., Weiner, D. J., Nehls, M. C., and Wilson, J. M. (1999). Mouse beta-defensin 3 is an inducible antimicrobial peptide expressed in the epithelia of multiple organs. Infect. Immun. 67, 3542–3547.

Bastian, A. and Schafer, H. (2001). Human alpha-defensin-1 (HNP-1) inhibits adenoviral infection in vitro. Regul. Pept. 101, 157–161.

Bateman, A., MacLeod, R. J., Lembessis, P., Hu, J., Esch, F., and Solomon, S. (1996). The isolation and characterization of a novel corticostatin/defensin-like peptide from the kidney. J. Biol. Chem. 271, 10654–10659.

Bensch, K. W., Raida, M., Magert, H. J., Schulz-Knappe, P., and Forssmann, W. G. (1995). hBD-1: A novel beta-defensin from human plasma. FEBS Lett. 368, 331–335.

Bevins, C. L., Jones, D. E., Dutta, A., Schaffzin, J., and Muenke, M. (1996). Human enteric defensin genes: Chromosomal map position and a model for possible evolutionary relationships. Genomics 31, 95–106.

Biragyn, A., Ruffini, P. A., Leifer, C. A., Klyushnenkova, E., Shakhov, A., Chertov, O., Shirakawa, A. K., Farber, J. M., Segal, D. M., Oppenheim, J. J., and Kwak, L. W. (2002). Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 298, 1025–1029.

Borenstein, L. A., Ganz, T., Sell, S., Lehrer, R. I., and Miller, J. N. (1991). Contribution of rabbit leukocyte defensines to the host response in experimental syphilis. Infect. Immun. 59, 1368–1377.

Borregaard, N., Sehested, M., Nielsen, B. S., Senglev, H., and Kjeldsen, L. (1995). Biosynthesis of granule proteins in normal human bone marrow cells: Gelatinase is a marker of terminal neutrophil differentiation. Blood 85, 812–817.

Brandtzaeg, P., Gabrielsen, T. O., Dale, I., Muller, F., Steinbakk, M., and Fagerhol, M. K. (1995). The leucocyte protein L1 (calprotectin): A putative nonspecific defence factor at epithelial surfaces. Adv. Exp. Med. Biol. 371A, 201–206.

Canny, G., Levy, O., Furuta, G. T., Narravula-Alipati, S., Sisson, R. B., Serhan, C. N., and Colgan, S. P. (2002). Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc. Natl. Acad. Sci. USA 99, 3902–3907.

Chamnompol, S., Cromie, M., and Groisman, E. A. (2003). Mg2+ Sensing by the Mg2+ Sensor PhoQ of Salmonella enterica. J. Mol. Biol. 325, 795–807.

Chertov, O., Michel, D. F., Xu, L., Wang, J. M., Tani, K., Murphy, W. J., Longo, D. L., Taub, D. B., and Oppenheim, J. J. (1996). Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J. Biol. Chem. 271, 2935–2940.

Cociancich, S., Goyffon, M., Bontems, F., Bulet, P., Bouet, F., Menez, A., and Hoffmann, J. (1993). Purification and characterization of a scorpion defense, a 4kDa antibacterial peptide presenting structural similarities with insect defensins and scorpion toxins. Biochem. Biophys. Res. Commun. 194, 17–22.

Cole, A. M., Shi, J., Ceccarelli, A., Kim, Y. H., Park, A., and Ganz, T. (2001). Inhibition of neutrophil elastase prevents cathelicidin activation and impairs clearance of bacteria from wounds. Blood 97, 297–304.
Chapter 6 Defensins and Other Antimicrobial Peptides and Proteins

Cole, A. M., Hong, T., Boo, L. M., Nguyen, T., Zhao, C., Bristol, G., Zack, J. A., Waring, A. J., Yang, O. O., and Lehrer, R. I. (2002). Retrocytocin: A primate peptide that protects cells from infection by HIV and M-epitopic strains of HIV-1. Proc. Natl. Acad. Sci. USA 99, 1813–1818.

Collins, L. V., Kristian, S. A., Weidenmaier, C., Faigle, M., van Kessel, K. P., van Strijp, J. A., Gotz, F., Neumeister, B., and Peschel, A. (2002). Staphylococcus aureus strains lacking D-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice. J. Infect. Dis. 186, 107–119.

Couto, M. A., Harwig, S. S., Cullor, J. S., Hughes, J. P., and Lehrer, R. I. (1992). eCAP-18, a cysteine-rich bactericidal peptide from equine leukocytes. Infect. Immun. 60, 5420–5427.

Cowlend, J. B., Johnsen, A. H., and Borregaard, N. (1995). hCAP-18, a cathelin/pro-bactenecin-like protein of human neutrophil specific granules. FEBS Lett. 368, 173–176.

Daher, K. A., Selsted, M. E., and Lehrer, R. I. (1986). Direct inactivation of viruses by human granulocyte defensins. J. Virol. 60, 1068–1074.

De,Y., Chen, Q., Schmidt, A. P., Anderson, G. M., Wang, J. M., Wang, J. M., Wooters, J. M., and Lehrer, R. I. (1986). Direct inactivation of viruses by human granulocyte defensins. J. Virol. 60, 1068–1074.

Driscoll, P. C., Gronenborn, A. M., Beress, L., and Clore, G. M. (1989). Paneth cell antimicrobial peptide, a cysteine-rich peptide from mammalian tracheal mucosa: Peptide isolation and cloning of a cDNA. Proc. Natl. Acad. Sci. USA 86, 3952–3956.

Driscoll, P. C., Gronenborn, A. M., Beress, L., and Clore, G. M. (1989). Determination of the three-dimensional solution structure of the antihypertensive and antiviral protein BDS-1 from the sea anemone Anemonia sulcata: A study using nuclear magnetic resonance and hybrid distance geometry-dynamical simulated annealing. Biochemistry 28, 2188–2198.

Eisenbauer, P. B., Harwig, S. S., and Lehrer, R. I. (1992). Cryptidins: Antimicrobial defensins of the marine small intestine. Infect. Immun. 60, 3556–3565.

Elsbach, P., and Weiss, J. (1998). Role of the bacterial/permeability-increasing protein in host defence. Curr. Opin. Immunol. 10, 45–49.

Ernst, R. K., Guina, T., and Miller, S. I. (2000). The human gene FALL39. FASEB J. 15, 1819–1821.

Evans, E. W., Beach, G. G., Wunderlich, J., and Harmon, B. G. (1994). Isolation of antimicrobial peptides from avian heterophils. J. Leukoc. Biol. 56, 661–665.

Evans, E. W., Beach, G. G., Moore, K. M., Jackwood, M. W., Glisson, J. R., and Harmon, B. G. (1995). Antimicrobial activity of chicken and turkey heterophilic peptides CHP1, CHP2, THP1, and THP3. Vet. Microbiol. 47, 295–303.

Fleischmann, J., Selsted, M. E., and Lehrer, R. I. (1985). Opsocnic activity of MCP-1 and MCP-2, cationic peptides from rabbit alveolar macrophages. Diagn. Microbiol. Infect. Dis. 3, 233–242.

Fox, J. W., Etinga, M., and Tu, A. T. (1979). Amino acid sequence and disulfide bond assignment of myotocin a isolated from the venom of Prairie rattlesnake (Crotalus viridis viridis). Biochemistry 18, 678–684.

Frohm, M., Agerberth, B., Ahangari, G., Stähle-Backdahl, M., Liden, S., Wiegell, H., and Gudmundsson, G. H. (1997). The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J. Biol. Chem. 272, 15258–15263.

Gallo, R. L., Ono, M., Povsic, T., Page, C., Eriksson, E., Klagsbrun, M., and Silverstrum, W. O. (2000). Antimicrobial peptides of phagocytes and epithelia. Semin. Hematol. 37, 343–354.

Ganz, T., and Weiss, J. (1997). Antimicrobial peptides of phagocytes and epithelia. Semin. Hematol. 34, 343–354.

Ganz, T., Gabayan, V., Liao, H. I., Liu, L., Oren, A., Graf, T., and Cole, A. M. (2003). Increased inflammation in lysosome M-deficient mice in response to Micrococcus luteus and its peptidoglycan. Blood 101, 2388–2392.

Garcia, J. R., Jaumann, F., Schulz, S., Krause, A., Rodriguez-Jimenez, J., Forssmann, U., Adermann, K., Kluver, E., Vogelmeier, C., Becker, D., Hedrich, R., Forssmann, W. G., and Bals, R. (2001a). Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity: Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemotraction. Cell Tissue Res. 306, 257–264.

Garcia, J. R., Krause, A., Schulz, S., Rodriguez-Jimenez, J. F., Kluver, E., Adermann, K., Forssmann, U., Frimpont-Boetang, A., Bals, R., and Forssmann, W. G. (2001b). Human beta-defensin 4: A novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. FASEB J. 15, 1819–1821.

Ghosh, D., Porter, E., Shen, B., Lee, S. K., Wilk, D., Drazba, J., Yadv, S. P., Crabb, J. W., Ganz, T., and Bevins, C. L. (2002). Paneth cell trepsin is the processing enzyme for human defensin-5. Nat. Immunol. 3, 583–590.

Goldman, M., Anderson, G., Stolzenberg, E. D., Kari, U. P., Zasloff, M., and Wilson, J. M. (1997). Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88, 553–560.

Gropp, R., Frye, M., Wagner, T. O., and Bargon, J. (1999). Epithelial defensins impair adenoviral infection: Implication for adenovirus-mediated gene therapy. Hum. Gene Ther. 10, 957–964.

Gudmundsson, G. H., Agerberth, B., Odeberg, J., Bergman, T., Olsson, B., and Salcedo, R. (1996). The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur. J. Biochem. 238, 325–332.

Guina, T., Yi, E. C., Wang, H., Hackett, M., and Miller, S. I. (2000). Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity: Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemotraction. Cell Tissue Res. 306, 257–264.
Harwig, S. E., Tan, L., Qu, X. D., Cho, Y., Eisenhauer, P. B., and Lehrer, R. I. (1995). Bacterial properties of murine intestinal phospholipase A2. J. Clin. Invest. 95, 603–610.

Hiemstra, P. S., Maassen, R. J., Stolk, J., Heinzl-Wieland, R., Steffens, G. J., and Dijkman, J. H. (1996). Antibacterial activity of antineutrophopetase. Infect. Immun. 64, 4520–4524.

Hiemstra, P. S. (2002). Novel roles of protease inhibitors in infection and inflammation. Biochim. Soc. Trans. 30, 116–120.

Hill, C. P., Yee, J., Selsted, M. E., and Eisenberg, D. (1991). Crystal structure of defense HNP-3, an amphiphilic dimer: Mechanisms of membrane permeabilization. Science 251, 1481–1485.

Hirata, M., Zhong, J., Wright, S. C., and Larrick, J. W. (1995). Structure and functions of endotoxin-binding peptides derived from CAP18. Prog. Clin. Biol. Res. 392, 317–326.

Hooper, L. V., Stappenbeck, T. S., Hong, C. V., and Gordon, J. I. (2003) Angiogenins: A new class of microbial defense proteins involved in innate immunity. Nat. Immunol. 4, 269–273.

Hoover, D. M., Rajashankar, K. R., Blumenthal, R., Puri, A., Oppenheim, J. J., Chertov, O., and Lubkowski, J. (2001). The structure of human beta-defensin-2 shows evidence of higher-order oligomerization. J. Biol. Chem. 276, 32911–32918.

Hoover, D. M., Chertov, O., and Lubkowski, J. (2001). The structure of human beta-defensin-1. New insights into structural properties of beta-defensins. J. Biol. Chem. 276, 39021–39026.

Huttner, K. M., Kozak, C. A., and Bevins, C. L. (1997). The mouse genome encodes a single homolog of the antimicrobial peptide human beta-defensin 1. FEBS Lett 413, 45–49.

Jia, H. P., Wowk, S. A., Schutte, B. C., Lee, S. K., Vivado, A., Tack, B. F., Bevins, C. L., and McCray, P. B., Jr. (2000). A novel murine beta-defensin expressed in tongue, esophagus, and trachea. J. Biol. Chem. 275, 33314–33320.

Jia, H. P., Schutte, B. C., Schudy, A., Linzmeier, R., Guthmiller, J. M., Johnson, G. K., Tack, B. F., Mitros, J. F., Rosenthal, A., Ganz, T., and McCray, P. B., Jr. (2001). Discovery of new human beta-defensins using a genomics-based approach. Gene 263, 211–218.

Joiner, K. A., Ganz, T., Albert, J., and Rotrosen, D. (1989). The opsonizing ligand on Salmonella typhimurium influences incorporation of specific, but not azurophil, granule constituents into neutrophil phagosomes. J. Cell Biol. 109, 2771–2782.

Jones, D. E. and Bevins, C. L. (1992). Paneth cells of the human small intestine express an antimicrobial peptide gene. J. Biol. Chem. 267, 23216–23225.

Jones, D. E. and Bevins, C. L. (1993). Defensin-6 mRNA in human intestine express an antimicrobial peptide gene. J. Biol. Chem. 268, 23226–23232.

Kagan, B. L., Selsted, M. E., Ganz, T., and Lehrer, R. I. (1990). Anti-microbial and anti-viral properties of mammalian cells. Annu. Rev. Immunol. 11, 105–128.

Lee, K. R., Boyak, F. N., Chertov, O., Oppenheim, J. J., and McGhee, J. R. (1997). Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc. Natl. Acad. Sci. USA 96, 651–656.

Linzmeier, R., Michaelson, D., Liu, L., and Ganz, T. (1993). The structure of neutrophil defensin genes. FEBS Lett. 321, 267–273.

Linzmeier, R., Ho, C. H., Hoang, B. V., and Ganz, T. (1999). A 45-kb contig of defensin genes on human chromosome 8p23. Gene 233, 205–211.

Liu, L., and Ganz, T. (1995). The pro region of human neutrophil defensin contains a motif that is essential for normal subcellular sorting. Blood 85, 1095–1103.

Liu, L., Zhao, C., Heng, H. H. Q., and Ganz, T. (1997). The human beta-defensin-1 and alpha-defensins are encoded by adjacent genes. Two peptide families with differing disulfide topology share a common ancestry. Genomics 43, 316–320.

Liu, L., Wang, L., Jia, H. P., Zhao, C., Heng, H. H. Q., Schutte, B. C., McCray, P. B. J., and Ganz, T. (1998). Structure and mapping of the human beta-defensin HBBD-2 gene and its expression at sites of inflammation. Gene 222, 237–244.

Liu, A. Y., Destoumieux, D., Wong, A. V., Park, C. H., Valore, E. V., Liu, L., and Ganz, T. (2002). Human beta-defensin-2 production in keratinocytes is regulated by IL-1, bacteria, and the state of differentiation. J. Invest. Dermatol. 118, 275–281.

Liu, L., Roberts, A. A., and Ganz, T. (2003). By IL-1 signaling, mono-ocyte-derived cells dramatically enhance the epidermal antimicrobial response to lipopolysaccharide. J. Immunol. 170, 575–580.

Lusitani, D., Malavista, S. E., and Montgomery, R. R. (2002). Borelia burgdorferi are susceptible to killing by a variety of human polymorphonuclear leukocyte components. J. Infect. Dis. 185, 797–804.

Mallow, E. B., Harris, A., Salzman, N., Russell, J. P., DeBerardinis, R. J., Ruchelli, E., and Bevins, C. L. (1996). Human enteric defensins: Gene structure and developmental expression. J. Biol. Chem. 271, 4038–4045.

Malm, J., Sorensen, O., Persson, T., Frohm-Nilsson, M., Johansson, B., Bjartell, A., Lilja, H., Stable-Backdahl, M., Borregaard, N., and Egesten, A. (2000). The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozooa. Infect. Immun. 68, 4297–4302.

Manitz, M. P., Horat, B., Seeleger, S., Strey, A., Skryabin, B. V., Gunzer, M., Frings, W., Schonlau, F., Roth, J., Sorg, C., and Hacken, W. (2003). Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol. Cell. Biol. 23, 1034–1043.

Marquardt, H., Todaro, G. J., and Twardzik, D. R. Swan venom gram negative arresting peptide. Oncogen and Seattle, WA. (US 4774318-A 3). 9-27-1988. (U.S. Patent Office Register).

Martinez de Tejada, G., Pizarro-Cerda, J., Moreno, E., and Moriyon, I. (1993). The outer membranes of Brucella spp. are resistant to bactericidal cationic peptides. Infect. Immun. 63, 3054–3061.

Masuda, K., Kamimura, T., Watanabe, K., Sug, T., Kanesaki, M., Takeuchi, A., Imazumi, A., and Suzuki, Y. (1995). Pharmacological activity of the C-terminal and N-terminal domains of secretory leukoprotease inhibitor in vitro. Br. J. Pharmacol. 115, 883–892.

McCray, P. B. J., and Bentley, L. (1997). Human airway epithelia express a beta-defensin. Am. J. Respir. Cell Mol. Biol. 16, 343–349.

Miller, S. I., Pulkkinen, W. S., Selsted, M. E., and Mekalanos, J. J. (1990). Characterization of defensin resistance phenotypes associated with mutations in the phoP virulence regulon of Salmonella typhimurium. Infect. Immun. 58, 3706–3710.
Chapter 6 Defensins and Other Antimicrobial Peptides and Proteins

Miyakawa, Y., Ratnakar, P., Rao, A. G., Costello, M. L., Mathieu-Costello, O., Lehrer, R. L., and Catanazzo, A. (1996). *In vitro* activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against *Mycobacterium tuberculosis*. *Infect. Immun.* 64, 926–932.

Morrison, G. M., Davidson, D. J., and Dorin, J. R. (1999). A novel mouse beta defensin, Defb2, which is upregulated in the airways by lipopolysaccharide. *FEBS Lett.* 442, 112–116.

Morrison, G., Kilanowski, F., Davidson, D., and Dorin, J. (2002). Characterization of the mouse beta defensin 1, Defb1, mutant mouse model. *Infect. Immun.* 70, 3033–3046.

Moser, C., Weiner, D. J., Lensken, E., Bals, R., Weiiser, J. N., and Wilson, J. M. (2002). beta-Defensin 1 contributes to pulmonary innate immunity in mice. *Infect. Immun.* 70, 3068–3072.

Murphy, C. J., Foster, B. A., Mannis, M. J., Selsted, M. E., and Reid, T. W. (1993). Defensins are mitogenic for epithelial cells and fibroblasts. *J. Cell Physiol.* 155, 408–413.

Nizet, V., Ohtake, T., Lauth, X., Trowbridge, J., Rudsill, J., Dorschner, M. E. (2000). Characterization of luminal Paneth cell alpha-defensin-2 is packaged in lamellar bodies. *Exp. Mol. Path.* 74, 180–182.

Ouellette, A. J., Greco, R. M., James, M., Frederick, D., Hagen, S. J., and McCray, P. B. (2001). Discovery of new human beta-defensins. *J. Biol. Chem.* 276, 28372–28379.

Panyutich, A., Shi, J., Boutz, P. L., Zhao, C., and Ganz, T. (1997). Chemokine receptor CCR6. *J. Exp. Med.* 180, 137–145.

Peng, J. H., Schutte, B. C., Schudy, A., Linzmeier, R., Guthmiller, J. M., Johnson, G. K., Tack, B. F., Mitros, J. P., Rosenthal, A., Ganz, T., and McCray, P. B. (2001). Discovery of new human beta-defensins using a genomics-based approach. *J. Biol. Chem.* 276, 28372–28379.

Porter, E. M., Liu, O., Aten, P. A., and Ganz, T. (1997a). Localization of human intestinal defensin 5 in Paneth cell granules. *Infect. Immun.* 65, 2389–2396.

Porter, E. M., vanDam, E., Valore, E. V., and Ganz, T. (1997b). Broad-spectrum antimicrobial activity of human intestinal defensin 5. *Infect. Immun.* 65, 2396–2401.

Porter, E. M., Poles, M. A., Lee, J. S., Naitoh, J., Bevins, C. L., and Ganz, T. (1998). Isolation of human intestinal defensins from ileal neobladder urine. *PEBS Lett.* 434, 272–276.

Putsep, K., Axelsson, L. G., Boman, A., Midveldt, T., Normark, S., Boman, H. G., and Andersson, M. (2000). Germ-free and colonized mice generate the same products from enteric protegrins. *J. Biol. Chem.* 275, 40874–40878.

Qu, X. D., Harwig, S. S., Oren, A. M., Shafer, W. M., and Lehrer, R. I. (1996a). Susceptibility of *Neisseria gonorrhoeae* to protegrins. *Infect. Immun.* 64, 1240–1245.

Qu, X. D., Lloyd, K. C., Walsh, J. H., and Lehrer, R. I. (1996b). Secretion of type II phospholipase A2 and cryptdin by rat small intestinal Paneth cells. *Infect. Immun.* 64, 513–517.

Rosenberg, H. F. and Domachowske, J. B. (2001). Eosinophils, eosinophil ribonucleases, and their role in host defense against respiratory virus pathogens. *J. Leukoc. Biol.* 70, 691–698.

Russell, J. P., Diamond, G., Tarver, A. P., Scanlin, T. F., and Bevins, C. L. (1996). Coordinate induction of two antibiotic genes in tracheal epithelial cells exposed to the inflammatory mediators lipopolysaccharide and tumor necrosis factor alpha. *Infect. Immun.* 64, 1565–1568.

Saito, T., Kawabata, S., Shigenaga, T., Takayenokyo, Y., Cho, J., Nakajima, H., Hirata, M., and Iwasaka, S. (1995). A novel big defensin identified in horeshoe crab hemocytes: Isolation, amino acid sequence, and antibacterial activity. *J. Biochem. (Tokyo)* 117, 1137–1143.

Salzman, N., Ghosh, D., Huttner, K. M., Paterson, Y., and Bevins, C. L. (2003). Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. *Nature* 422, 522–526.

Sato, Y. (1988). Effect of live and heat-killed bacteria on the secretory activity of Paneth cells in germ-free mice. *Cell Tissue Res.* 251, 87–93.

Sawyer, J. G., Holmberg, E. D., and Hancock, R. E. (1988). Interaction of macrophage cationic proteins with the outer membrane of *Pseudomonas aeruginosa*. *Infect. Immun.* 56, 693–698.

Scheetz, T., Bartlett, J. A., Walters, J. D., Schutte, B. C., Casvant, T. L., and PB Jr, B. M. (2002). Genomics-based approaches to gene discovery in innate immunity. *Immunol. Rev.* 190, 137–145.

Schibl, D. J., Hunter, H. N., Aseyev, V., Sturmer, T. D., Wierzbicki, J. M., McCray, P. B., Jr., Tack, B. F., and Vogel, H. J. (2002). The solution structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of HBDD3 against *Staphylococcus aureus*. *J. Biol. Chem.* 277, 8279–8289.

Schonwetter, B. S., Stolzenberg, E. D., and Zasloff, M. A. (1995). Epithelial antibiotics induced at sites of inflammation. *Science* 267, 1645–1648.

Schutte, B. C., Mitros, J. P., Bartlett, J. A., Walters, J. D., Jia, H. P., Welsh, M. J., Casvant, T. L., and McCray, P. B., Jr. (2002). Discovery of five conserved beta-defensin gene clusters using a computational search strategy. *Proc. Natl. Acad. Sci. USA* 99, 2123–2133.

Scooch, C. E., Skerlavaj, B., Romeo, D., and Gennaro, R. (1992). Proteolytic cleavage by neutrophil elastase converts inactive storage proforms to antibiotic bactericidal activities. *Eur. J. Biochem.* 209, 589–595.

Selsted, M. E., Miller, S. I., Hensch, A. H., and Ouellette, A. J. (1992). Enteric defensins: Antibiotic peptide components of intestinal host defense. *J. Cell Biol.* 118, 929–936.

Selsted, M. E., Tang, Y. Q., Morris, W. L., McGuire, P. A., Novotny, M. J., Smith, W., Hensch, A. H., and Cullor, J. S. (1993). Purification, primary structures, and antibacterial activities of beta-defensins, a new family of antimicrobial peptides from bovine neutrophils. *J. Biol. Chem.* 268, 6641–6648.

Shafer, W. M., Qi, X., Waring, A. J., and Lehrer, R. I. (1998). Modulation of *Neisseria gonorrhoeae* susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. *Proc. Natl. Acad. Sci. USA* 95, 1829–1833.

Sharma, S., and Khuller, G. (2001). DNA as the intracellular secondary target for antibacterial action of human neutrophil peptide-I against *Mycobacterium tuberculosis H37Rv*. *Curr. Microbiol.* 43, 74–76.

Sharma, S., Verma, I., and Khuller, G. K. (2000). Antibacterial activity of human neutrophil peptide-I against *Mycobacterium tuberculosis H37Rv*: *In vitro* and *ex vivo* study. *Eur. Respir.* 16, 112–117.

Shi, J., and Ganz, T. (1998). The role of protegrins and other elastase-activated polypeptides in the bactericidal properties of porcine inflammatory fluids. *Infect. Immun.* 66, 3611–3617.
Singh, P. K., Parsek, M. R., Greenberg, E. P., and Welsh, M. J. (2002). A component of innate immunity prevents bacterial biofilm development. *Nature* 417, 352–355.

Sinha, S., Cheshenko, N., Lehrer, R. I., and Herold, B. C. (2003). NP-1, a rabbit alpha-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2. *Antimicrob. Agents Chemother.* 47, 494–500.

Smith, J. J., Travis, S. M., Greenberg, E. P., and Welsh, M. J. (1996). Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. *Cell* 85, 229–236.

Sorensen, O. E., Follin, P., Johnsen, A. H., Calafat, J., Tjahringa, G. S., Hiemstra, P. S., and Borregaard, N. (2001). Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. *Blood* 97, 3951–3959.

Stolzenberg, E. D., Anderson, G. M., Ackermann, M. R., Whitlock, R. H., and Sasloff, M. (1997). Epithelial antibiotic induced in states of disease. *Proc. Natl. Acad. Sci. USA* 94, 8686–8690.

Tang, Y. Q., Yuan, J., Osapay, G., Osapay, K., Tran, D., Miller, C. J., Ouette, A. J., and Selsted, M. E. (1999). A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins. *Science* 286, 498–502.

Tarver, A. P., Clark, D. F., Diamond, G., Russell, J. P., Erdjument-Bromage, H., Tempst, P., Cohen, K. S., Jones, D. E., Sweeney, R. W., Wines, M., Hwang, S., and Bevins, C. L. (1998). Enteric beta-defensin: Molecular cloning and characterization of a gene with inducible intestinal epithelial cell expression associated with *Cryptosporidium parvum* infection. *Infect. Immun.* 66, 1045–1056.

Territo, M. C., Ganz, T., Selsted, M. E., and Lehrer, R. (1989). Monocyte-chemotactic activity of defensins from human neutrophils. *J. Clin. Invest.* 84, 2017–2020.

Thevissen, K., Terras, F. R., and Broekaert, W. F. (1999). Permeabilization of fungal membranes by plant defensins inhibits fungal growth. *Appl. Environ. Microbiol.* 65, 5451–5458.

Thomma, B. P., Cammue, B. P., and Thevissen, K. (2002). Plant defensins. *Planta* 216, 193–202.

Tomita, M., Takase, M., Wakabayashi, H., and Bellamy, W. (1994). Antimicrobial peptides of lactoferrin. *Adv. Exp. Med. Biol.* 357, 209–218.

Valore, E. V., and Ganz, T. (1992). Posttranslational processing of defensins in immature human myeloid cells. *Blood* 79, 1538–1544.

Valore, E. V., Park, C. H., Quayle, A. J., Wiles, K. R., McCray, P. B., and Ganz, T. (1998). Human beta-defensin-1: An antimicrobial peptide of urogenital tissues. *J. Clin. Invest.* 101, 1633–1642.

Van Wetering, S., Mannaes-Lazemors, S. P., van Sterkenburg, M. A., Daha, M. R., Dijkman, J. H., and Hiemstra, P. S. (1997). Effect of defensins on interleukin-8 synthesis in airway epithelial cells. *Am. J. Physiol.* 272, L888–L896.

Viljanen, P., Koski, P., and Vaara, M. (1988). Effect of small cationic leukocyte peptides (defensins) on the permeability barrier of the outer membrane. *Infect. Immun.* 56, 2324–2329.

Weinrauch, Y., Elsbach, P., Madsen, L. M., Foreman, A., and Weiss, J. (1996). The potent anti-*Staphylococcus aureus* activity of a sterile rabbit inflammatory fluid is due to a 14-kD phospholipase A2. *J. Clin. Invest.* 97, 250–257.